Topographical distribution of [125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection

Brain Research

Volumn 789, Issue 1, 1998, Pages 9-22

  Lapchak, P A ^a   Araujo, D M ^a   Hilt, D C ^a   Jiao, S ^a   Collin, F ^a   Miyoshi, Y ^b   Yi, A ^b   Zhang, Z ^b   Gash, D M ^b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

GDNF; Immunocytochemistry; Neurotrophic factor; Parkinson's disease; Substantia nigra

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NERVE PROTEIN; RADIOACTIVE IODINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; FEMALE; GLIA CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RHESUS MONKEY; SUBSTANTIA NIGRA; ANIMAL; BRAIN; DRUG EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MACACA; METABOLISM; REFERENCE VALUE; TISSUE DISTRIBUTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INJECTIONS, INTRAVENTRICULAR; IODINE RADIOISOTOPES; MACACA MULATTA; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; REFERENCE VALUES; TISSUE DISTRIBUTION; TYROSINE 3-MONOOXYGENASE;

EID: 0032489683     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01495-9     Document Type: Article

References (25)

1. Bowenkamp K.E., David D., Lapchak P.A., Henry M.A., Granholm A.C., Hoffer B.J., Mahalik T.J. 6-Hydroxydopamine induced the loss of the dopaminergic phenotype in substantia nigra neurons in the rat - a possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp. Brain Res. 111:1996;1-7.
2. Bowenkamp K.E., Hoffman A.F., Gerhardt G.A., Henry M.A., Biddle P.T., Hoffer B.J., Granholm A.-C.E. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355:1995;479-489.
3. Gash D.M., Zhang Z., Cass W.A., Ovadia A., Simmerman L., Martin D., Russell D., Collins F., Hoffer B.J., Gerhardt G.A. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. Comp. Neurol. 363:1995;345-358.
4. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. GDNF promotes functional recovery in Parkinsonian monkeys. Nature. 380:1996;252-255.
5. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L.-F.H., Gerhardt G. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182:1994;107-111.
6. Hornykiewicz O., Fish S.J. Biochemical pathophysiology in Parkinson's disease. Adv. Neurol. 45:1986;19-34.
7. Hudson J., Granholm A.-C., Gerhardt G.A., Henry M.A., Hoffman A., Biddle P., Leele N.S., Mackerlova L., Lile J.D., Collins F., Hoffer B.J. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36:1995;425-432.
8. Kearns C., Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672:1995;104-111.
9. Kitt C.A., Cork L.C., Eidelberg F., Joh T.H., Price D.L. Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey. Neuroscience. 17:1986;1089-1103.
10. Kupsch A., Oertel W.H., Earl C.D., Sautter J. Neuronal transplantation and neurotrophic factors in the treatment of Parkinson's disease - update February 1995. J. Neural Transm. Suppl. 46:1995;193-207.
11. Lapchak P.A., Jiao S.S., Miller P.J., Williams L.R., Cummins V., Inouye G., Matheson C.R., Yan Q. Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule to treat neurodegenerative diseases. Cell Tissue Res. 286:1996;179-189.
12. Lapchak P.A. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev. Neurosci. 7:1996;165-176.
13. Lapchak P.A., Miller P.J., Jiao S., Araujo D.M., Hilt D., Collins F. Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration. 5:1996;197-205.
14. Lapchak P.A., Gash D.M., Collins F.C., Hilt D., Miller P.J., Araujo D.M. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development pharmacological activities and application to the treatment of Parkinson's disease. Exp. Neurol. 145:1997;309-321.
15. Lapchak P.A., Miller P.J., Jiao S. Glial cell line-derived neurotrophic factor (GDNF) induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged F344 rats. Neuroscience. 77(3):1997;745-752.
16. Lapchak P.A., Gash D.M., Jiao S., Miller P.J., Hilt D. Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Exp. Neurol. 144:1997;29-34.
17. Lapchak P.A., Jiao S., Collins F., Miller P.J. Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res. 747:1997;92-102.
18. Lapchak P.A., Miller P.J., Collins F., Jiao S.S. Glial cell line-derived neurotrophic factor (GDNF) attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience. 78:1997;61-72.
19. Leenders K.L., Salmon E.P., Tyrrell P., Perani D., Brooks D.J., Sager H., Jones T., Marsden D., Franchowiak R.S.J. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteers and in patients with Parkinson's disease. Arch. Neurol. 47:1993;1290-1298.
20. Lin L.-F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
21. Lin L.-F., Zhang T.J., Collins F., Armes L.G. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J. Neurochem. 63:1994;758-768.
22. 3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur. J. Pharmacol. 156:1988;331-340.
23. C.D. Marsden, J.D. Parkes, N. Quinn, Fluctuations of disability in Parkinson's disease - clinical aspects, in: C.D. Marsden, S. Fahn (Eds.), Movement Disorders, Butterworth, London, 1982, pp. 96-122.
24. Miyoshi Y., Zhang Z., Ovadia A., Kryscio R., Lapchak P.A., Hilt D., Lebel C., Collins F., Gash D.M. GDNF-Levodopa interactions and reduction of side effects in Parkinsonian monkeys. Ann. Neurol. 42:1997;208-214.
25. Tomac A., Widenfalk J., Lin L.-F.H., Kohno T., Ebendal T., Hoffer B.J., Olson L. Retrograde axonal transport of GDNF in the adult nigrostriatal system supports a trophic role in the adult. PNAS (USA). 92:1995;8274-8278.